Nicotine, cotinine, and β-nicotyrine inhibit NNK-induced DNA-strand break in the hepatic cell line HepaRG

Toxicology in Vitro

Volumn 28, Issue 7, 2014, Pages 1329-1337

  Ordonez, Patricia ^a   Sierra, Ana Belen ^a   Camacho, Oscar M ^b   Baxter, Andrew ^b   Banerjee, Anisha ^b   Waters, David ^b   Minet, Emmanuel ^b  

^a VIVOTECNIA   (Spain)

^b BAT Group Research and Development   (United Kingdom)

Author keywords

Bioactivation; COMET; Cotinine; DNA strand break; Nicotine; NNK

Indexed keywords

2 BUTANONE; 4 (ACETOXYMETHYLNITROSOAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; ALKALOID; COTININE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2B7; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ISOTHIOCYANIC ACID; MESSENGER RNA; METHOXSALEN; NICOTINE; NICOTYRINE; UNCLASSIFIED DRUG; 4-(N-METHYL-N-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; CYP2A6 PROTEIN, HUMAN; NITROSAMINE; PYRIDINE DERIVATIVE;

ARTICLE; CELL VIABILITY; COMET ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION PROFILING; HEPARG CELL; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER CELL; MOLECULAR INTERACTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; CELL CULTURE; DNA DAMAGE; DRUG EFFECTS; EPITHELIUM CELL; LIVER; METABOLISM; TUMOR CELL LINE;

NICOTIANA TABACUM;

CELL LINE, TUMOR; CELLS, CULTURED; COMET ASSAY; COTININE; CYTOCHROME P-450 CYP2A6; DNA DAMAGE; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; LIVER; NITROSAMINES; PYRIDINES;

EID: 84905057746     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.06.017     Document Type: Article

References (40)

1. Argentin G., Cicchetti R. Genotoxic and antiapoptotic effect of nicotine on human gingival fibroblasts. Toxicol. Sci. 2004, 79:75-81.
2. Ariyoshi N., Sawamura Y., Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem. Biophys. Res. Commun. 2001, 281:810-814.
3. Bao Z., He X.Y., Ding X., Prabhu S., Hong J.Y. Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab. Dispos. 2005, 33:258-261.
4. Bright J., Aylott M., Bate S., Geys H., Jarvis P., Saul J., Vonk R. Recommendations on the statistical analysis of the Comet assay. Pharm. Stat. 2011, 10:485-493.
5. Brown B.G., Chang C.J., Ayres P.H., Lee C.K., Doolittle D.J. The effect of cotinine or cigarette smoke co-administration on the formation of O6-methylguanine adducts in the lung and liver of A/J mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Toxicol. Sci. 1999, 47:33-39.
6. Cogliano V., Straif K., Baan R., Grosse Y., Secretan B., El G.F. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol. 2004, 5:708.
7. Denton T.T., Zhang X., Cashman J.R. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem. Pharmacol. 2004, 67:751-756.
8. Donato M.T., Viitala P., Rodriguez-Antona C., Lindfors A., Castell J.V., Raunio H., Gomez-Lechon M.J., Pelkonen O. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab. Dispos. 2000, 28:1321-1326.
9. Garcia-Canton C., Minet E., Anadon A., Meredith C. Metabolic characterization of cell systems used in in vitro toxicology testing: Lung cell system BEAS-2B as a working example. Toxicol. In Vitro 2013, 27:1719-1727.
10. Gerets H.H., Tilmant K., Gerin B., Chanteux H., Depelchin B.O., Dhalluin S., Atienzar F.A. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol. Toxicol. 2012, 28:69-87.
11. Gilmore J., Rotondo F., Pelletier A.M., LaMarre J., Alaoui-Jamali M., Kirby G.M. Identification of a 43-kDa protein in human liver cytosol that binds to the 3'-untranslated region of CYP2A6 mRNA. Biochem. Pharmacol. 2001, 62:669-678.
12. Hamilton S.M., Teel R.W. Effects of isothiocyanates on cytochrome P-450 1A1 and 1A2 activity and on the mutagenicity of heterocyclic amines. Anticancer Res. 1996, 16:3597-3602.
13. Hang B., Sarker A.H., Havel C., Saha S., Hazra T.K., Schick S., Jacob P., Rehan V.K., Chenna A., Sharan D., Sleiman M., Destaillats H., Gundel L.A. Thirdhand smoke causes DNA damage in human cells. Mutagenesis 2013, 28:381-391.
14. He X.Y., Shen J., Ding X., Lu A.Y., Hong J.Y. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Drug Metab. Dispos. 2004, 32:1516-1521.
15. Hecht S.S. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 1998, 11:559-603.
16. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999, 91:1194-1210.
17. Hecht S.S. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002, 23:907-922.
18. Hecht S.S., Carmella S.G., Foiles P.G., Murphy S.E. Biomarkers for human uptake and metabolic activation of tobacco-specific nitrosamines. Cancer Res. 1994, 54:1912s-1917s.
19. Hoffmann D., Rivenson A., Hecht S.S. The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Crit. Rev. Toxicol. 1996, 26:199-211.
20. Jalas J.R., Hecht S.S., Murphy S.E. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem. Res. Toxicol. 2005, 18:95-110.
21. Kramlinger V.M., von Weymarn L.B., Murphy S.E. Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, beta-nicotyrine and menthol. Chem. Biol. Interact. 2012, 197:87-92.
22. Maier C.R., Hollander M.C., Hobbs E.A., Dogan I., Linnoila R.I., Dennis P.A. Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prev. Res. (Phila) 2011, 4:1743-1751.
23. Maser E. 11Beta-hydroxysteroid dehydrogenase responsible for carbonyl reduction of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes. Cancer Res. 1998, 58:2996-3003.
24. Murphy S.E., von Weymarn L.B., Schutten M.M., Kassie F., Modiano J.F. Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis. Cancer Prev. Res. (Phila) 2011, 4:1752-1760.
25. Nakajima M., Yoshida R., Shimada N., Yamazaki H., Yokoi T. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab. Dispos. 2001, 29:1110-1113.
26. Newland N., Baxter A., Hewitt K., Minet E. CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol. In Vitro 2011, 25:922-929.
27. Nishioka T., Guo J., Yamamoto D., Chen L., Huppi P., Chen C.Y. Nicotine, through upregulating pro-survival signaling, cooperates with NNK to promote transformation. J. Cell Biochem. 2010, 109:152-161.
28. Peterson L.A., Mathew R., Murphy S.E., Trushin N., Hecht S.S. In vivo and in vitro persistence of pyridyloxobutyl DNA adducts from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 1991, 12:2069-2072.
29. Smith T.J., Guo Z., Gonzalez F.J., Guengerich F.P., Stoner G.D., Yang C.S. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res. 1992, 52:1757-1763.
30. Smith T.J., Stoner G.D., Yang C.S. Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res. 1995, 55:5566-5573.
31. Smith G.B., Castonguay A., Donnelly P.J., Reid K.R., Petsikas D., Massey T.E. Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells. Carcinogenesis 1999, 20:1809-1818.
32. Su T., Bao Z., Zhang Q.Y., Smith T.J., Hong J.Y., Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000, 60:5074-5079.
33. Thorne D., Wilson J., Kumaravel T.S., Massey E.D., McEwan M. Measurement of oxidative DNA damage induced by mainstream cigarette smoke in cultured NCI-H292 human pulmonary carcinoma cells. Mutat. Res. 2009, 673:3-8.
34. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 2000, 35:206-221.
35. Van Vleet T.R., Bombick D.W., Coulombe R.A. Inhibition of human cytochrome P450 2E1 by nicotine, cotinine, and aqueous cigarette tar extract in vitro. Toxicol. Sci. 2001, 64:185-191.
36. von Weymarn L.B., Brown K.M., Murphy S.E. Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J. Pharmacol. Exp. Ther. 2006, 316:295-303.
37. von Weymarn L.B., Chun J.A., Knudsen G.A., Hollenberg P.F. Effects of eleven isothiocyanates on P450 2A6- and 2A13-catalyzed coumarin 7-hydroxylation. Chem. Res. Toxicol. 2007, 20:1252-1259.
38. von Weymarn L.B., Retzlaff C., Murphy S.E. CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine D5'(1')iminium ion. J. Pharmacol. Exp. Ther. 2012, 343:307-315.
39. Yamazaki H., Inui Y., Yun C.H., Guengerich F.P., Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992, 13:1789-1794.
40. Zhang X., D'Agostino J., Wu H., Zhang Q.Y., Von Weymarn L., Murphy S.E., Ding X. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J. Pharmacol. Exp. Ther. 2007.